Oct 20 (Reuters) – Mabion SA: * PARTNER ODDIFACT SAYS FDA CONSULTATIONS ALLOW MABIONCD20 TO BE USED AS FIRST-LINE THERAPY FOR ITP * CLINICAL TRIAL OBSERVATION PERIOD FOR MABIONCD20 CAN BE SHORTENED TO
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 20 (Reuters) - Elisa Oyj: * SWISS-BASED POWEREDGE SELECTS ELISA INDUSTRIQ'S GRIDLE FOR 37…
HONG KONG/Tokyo, Oct 20 (Reuters) - Japanese banks Mizuho Financial Group and Daiwa Securities are…
By Leo Marchandon Oct 20 (Reuters) - OVHcloud expects to launch its first AI model…
Following is a summary of current sports news briefs. NHL roundup: Gavin McKenna leads Leafs…
Oct 20 (Reuters) - Telefonica : * TELEFONICA SIGNS DEFENSE CONNECTIVITY AND SECURITY COLLABORATION WITH…
Mumbai (Maharashtra) [India], October 20: Aayush Wellness Limited, an integrated healthcare company, has expanded its…